pharmaceutical investing InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
pharmaceutical investing InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
pharmaceutical investing InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
pharmaceutical investing InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
pharmaceutical investing InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
pharmaceutical investing InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
InMed Pharmaceuticals:Â Innovating Cannabinoid-inspired Medicines, Backed by Real Revenue and Clear Path to Value
Quebec Innovative Materials Corp. Announces U.S. Affiliate Orvian Receives Minnesota DNR Registration for Exploratory Boring
